Evaluation of the Effect of Atorvastatin Administration on the Outcomes of Patients with Traumatic Brain Injury: A Double-blinded Randomized Clinical Trial.
Atorvastatin
Glasgow Coma Scale (GCS)
Glasgow Outcome Scale (GOS)
Traumatic Brain Injury (TBI)
Journal
Anesthesiology and pain medicine
ISSN: 2228-7523
Titre abrégé: Anesth Pain Med
Pays: Netherlands
ID NLM: 101585412
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
received:
20
06
2021
revised:
01
08
2021
accepted:
06
08
2021
entrez:
25
10
2021
pubmed:
26
10
2021
medline:
26
10
2021
Statut:
epublish
Résumé
Traumatic brain injury (TBI) is one of the common causes of long-term disabilities and mortality. This study aimed to evaluate the effect of atorvastatin administration on the Glasgow Coma Scale (GCS), Glasgow Outcome Scale (GOS), and Disability Rating Scale (DRS) in patients with TBI. This double-blinded randomized clinical trial included 60 patients with TBI in Golestan Hospital of Ahvaz, Iran. After obtaining an informed consent from all patients, the patients were randomly assigned into two groups. For the intervention group, atorvastatin with a daily dose of 20 mg was used. The control group was administered the same amount of placebo for 10 days. Changes in the level of consciousness were measured using the GCS, and functional recovery rate in patients was measured by GOS and DRS in the third follow-up month. According to the obtained results, compared with the control group, the atorvastatin administration significantly increased the level of GCS and DRS within 2 - 3 months post-intervention and improved GOS since the tenth day after the study (P < 0.05). The results revealed the positive effect of atorvastatin on the improvement of outcomes measurements such as GCS, DRS, and GOS in patients after moderate and severe TBI.
Sections du résumé
BACKGROUND
BACKGROUND
Traumatic brain injury (TBI) is one of the common causes of long-term disabilities and mortality. This study aimed to evaluate the effect of atorvastatin administration on the Glasgow Coma Scale (GCS), Glasgow Outcome Scale (GOS), and Disability Rating Scale (DRS) in patients with TBI.
METHODS
METHODS
This double-blinded randomized clinical trial included 60 patients with TBI in Golestan Hospital of Ahvaz, Iran. After obtaining an informed consent from all patients, the patients were randomly assigned into two groups. For the intervention group, atorvastatin with a daily dose of 20 mg was used. The control group was administered the same amount of placebo for 10 days. Changes in the level of consciousness were measured using the GCS, and functional recovery rate in patients was measured by GOS and DRS in the third follow-up month.
RESULTS
RESULTS
According to the obtained results, compared with the control group, the atorvastatin administration significantly increased the level of GCS and DRS within 2 - 3 months post-intervention and improved GOS since the tenth day after the study (P < 0.05).
CONCLUSIONS
CONCLUSIONS
The results revealed the positive effect of atorvastatin on the improvement of outcomes measurements such as GCS, DRS, and GOS in patients after moderate and severe TBI.
Identifiants
pubmed: 34692441
doi: 10.5812/aapm.117140
pmc: PMC8520682
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e117140Informations de copyright
Copyright © 2021, Author(s).
Déclaration de conflit d'intérêts
Conflict of Interests: There was no conflict of interest to be declared.
Références
J Athl Train. 2016 Dec;51(12):1037-1044
pubmed: 27835042
J Clin Neurosci. 2017 Oct;44:143-147
pubmed: 28688622
J Head Trauma Rehabil. 2010 Mar-Apr;25(2):72-80
pubmed: 20234226
Anesth Pain Med. 2019 Apr 28;9(2):e90858
pubmed: 31341829
World Neurosurg. 2017 Jan;97:407-415
pubmed: 27744073
Anesth Pain Med. 2018 Feb 24;8(1):e57583
pubmed: 29868455
J Head Trauma Rehabil. 2006 Nov-Dec;21(6):544-8
pubmed: 17122685
Antioxidants (Basel). 2020 Apr 02;9(4):
pubmed: 32252390
Concussion. 2017 Feb 2;2(1):CNC29
pubmed: 30202570
Brain Behav Immun. 2012 Nov;26(8):1191-201
pubmed: 22728326
NeuroRehabilitation. 2016 Jun 30;39(3):345-9
pubmed: 27497467
Anesth Pain Med. 2020 Nov 21;11(1):e108561
pubmed: 34249664
Dis Model Mech. 2013 Nov;6(6):1307-15
pubmed: 24046353
Lancet. 2010 Nov 13;376(9753):1670-81
pubmed: 21067804
Injury. 2017 May;48(5):1040-1046
pubmed: 27914661
Surg Neurol. 2009 Aug;72(2):146-52; discussion 152
pubmed: 18786717
Mt Sinai J Med. 2009 Apr;76(2):97-104
pubmed: 19306379
Brain Inj. 2016;30(8):993-8
pubmed: 27119267
J Neurosurg. 2005 Oct;103(4):695-701
pubmed: 16266052
Anesth Pain Med. 2020 Sep 01;10(5):e106623
pubmed: 34150567
J Neurotrauma. 2017 Feb 27;:
pubmed: 28006970
Am Fam Physician. 2012 Jan 15;85(2):123-32
pubmed: 22335212
J Neurosurg. 2013 Mar;118(3):669-75
pubmed: 23289819
Anesth Pain Med. 2020 Mar 24;10(2):e98679
pubmed: 32754429
Anesth Pain Med. 2018 Dec 05;8(6):e83128
pubmed: 30719416
Iran Biomed J. 2013;17(3):152-7
pubmed: 23748894
J Clin Lipidol. 2012 Jan-Feb;6(1):42-9
pubmed: 22264573
Clin Neurol Neurosurg. 2016 Oct;149:1-5
pubmed: 27450760
J Neuroinflammation. 2017 Aug 23;14(1):167
pubmed: 28835272
J Head Trauma Rehabil. 2008 Mar-Apr;23(2):123-31
pubmed: 18362766
BMC Neurosci. 2009 Jan 21;10:7
pubmed: 19159448
Front Neurol. 2020 Aug 11;11:816
pubmed: 32849246